Literature DB >> 455886

Presystemic and systemic glucuronidation of propranolol.

T Walle, T C Fagan, E C Conradi, U K Walle, T E Gaffney.   

Abstract

The relative importance of presystemic and systemic glucuronidation of propranolol was examined in normal subjects given single oral and intravenous doses of propranolol. The areas under the plasma concentration--time curves (AUCs) of propranolol glucuronide (PG), 41 +/- 15 ng . hr/ml, and propranolol, 48 +/- 15 ng . hr/ml, were of the same order after the intravenous dose (0.05 mg/kg). After oral doses of 20 and 80 mg, the AUCs of PG were 302 +/- 105 and 1,398 +/- 409 ng . hr/ml; these were 7 times the AUCs of propranolol, 44 +/- 15 and 220 +/- 38 ng . hr/ml. The time lapse to peak concentration, 1.5 to 3.0 hr, and the plasma half-life, 3.2 to 3.7 hr, were the same for PG and propranolol. These results demonstrate glucuronidation as an important determinant of propranolol bioavailability.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 455886     DOI: 10.1002/cpt1979262167

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  15 in total

1.  Partial metabolic clearances as determinants of the oral bioavailability of propranolol.

Authors:  T Walle; U K Walle; L S Olanoff; E C Conradi
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

2.  Transdermal controlled delivery of propranolol from a multilaminate adhesive device.

Authors:  M Corbo; J C Liu; Y W Chien
Journal:  Pharm Res       Date:  1989-09       Impact factor: 4.200

3.  Chronic propranolol administration during pregnancy. Maternal pharmacokinetics.

Authors:  M T Smith; I Livingstone; M J Eadie; W D Hooper; E J Triggs
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Early kinetics of intravenous propranolol.

Authors:  T C Fagan; T Walle; U K Walle; E C Conradi; G Harmon; T E Gaffney
Journal:  Br J Clin Pharmacol       Date:  1982-04       Impact factor: 4.335

5.  Prediction of bioavailability for drugs with a high first-pass effect using oral clearance data.

Authors:  A Somogyi; M Eichelbaum; R Gugler
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

7.  The analysis and disposition of imipramine and its active metabolites in man.

Authors:  T A Sutfin; C L DeVane; W J Jusko
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

8.  Stereoselective ring oxidation of propranolol in man.

Authors:  T Walle; U K Walle; M J Wilson; T C Fagan; T E Gaffney
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

9.  Effects of chlorpromazine on the disposition and beta-adrenergic blocking activity of propranolol in the dog.

Authors:  S A Bai; F P Abramson
Journal:  J Pharmacokinet Biopharm       Date:  1984-06

Review 10.  Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors.

Authors:  H K Kroemer; U Klotz
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.